When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

Forbes contributors publish independent expert analyses and insights. I am a cable news contributor and professor of journalism. This voice experience is generated by AI. Learn more. This voice ...

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the ...